Business Context and Reporting Period
Company: Inmune Bio, Inc.
Filing Type: Form 8-K (Current Report)
Report Date: April 19, 2019
Event Date: April 17, 2019
Context: The filing reports a corporate event under Item 8.01 (Other Events) regarding a scientific presentation at the Neuroimmunology Drug Development Summit in Boston.
Key Financial Metrics
This Form 8-K does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing is limited to reporting a specific corporate event.
Material Changes
No financial material changes are reported in this document. The material event is the presentation of data regarding the Company's drug candidate, XPro1595.
Outlook, Commentary, and Risks
- Management Commentary: Christopher Baum, Ph.D., Director of Neuroscience and Translational Medicine, presented a poster addressing the Phase 1b trial on the drug candidate XPro1595.
- Event Details: The presentation occurred at the Neuroimmunology Drug Development Summit in Boston on April 17, 2019.
- Exhibit Status: The press release (Exhibit 99.1) is furnished but not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings.
- Emerging Growth Company: The registrant is identified as an emerging growth company.
Investor Verification Checklist
- Verify the content of the press release (Exhibit 99.1) for specific clinical data regarding the XPro1595 Phase 1b trial.
- Confirm the status of the Neuroimmunology Drug Development Summit presentation materials.
- Review subsequent filings for any financial impact or strategic shifts resulting from the trial data.